Comparison of the clinical efficacy of donafinil and lenvatinib in the treatment of intermediate and advanced hepatocellular carcinoma.

Objective: To compare the therapeutic effects of donafinil and lenvatinib in the treatment of patients with intermediate--advanced hepatocellular carcinoma (HCC).

Methods: A total of 100 patients with intermediate--advanced HCC who received donafinib or lenvatinib treatment in Hechi First People's Hospital, Hechi People's Hospital, the Second Affiliated Hospital of Guangxi University of Science and Technology, and other centers from January 2021 to June 2022 were retrospectively analyzed. The patients were classified into a donafinil group (n=50) and a lenvatinib group (n=50) according to the treatment method.